2015

1. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: Variation between label dosage and real-world use

   Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 15, Núm. 5, pp. 851-858